NeoGenomics opposes US PTAB discretionary denial, citing public health concerns
A bid by Natera Inc. to short-circuit inter partes review of its oncologic testing patent should be denied, petitioner NeoGenomics Laboratories told the US Patent Trial and Appeal Board yesterday, because...To view the full article, register now.
Already a subscriber? Click here to view full article